Insmed Inc. (Nasdaq: INSM) primarily
develops inhalation therapies for the treatment of lung diseases.
Insmed's most notable project is ARIKACE, an inhaled antibiotic for
patients suffering from cystic fibrosis and non-tuberculous
mycobacteria. Currently, ARIKACE is in phase II trials in the United
States and phase III trials in Canada and Europe.
INSM stock has gained an impressive 241% in the last year and
currently trades at $19.73. Insmed has a market cap of just $772
million, which also makes it an attractive takeover option for
large-cap pharmaceutical companies.
Acorda Therapeutics (Nasdaq: ACOR) provides
treatments for people suffering from multiple sclerosis (MS), spinal
cord injuries, and other nervous system disorders. The biggest product
for Acorda is Ampyra, which helps MS patients who have difficulty
walking. The company reported that through the first nine months of
2013, Ampyra sales had risen by 13%. Ampyra is already approved by the
U.S. Food and Drug Administration (FDA), and Acorda currently has three
FDA-approved drugs in its portfolio. (more)
Please share this article
No comments:
Post a Comment